Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic Acid, in rats and humans.

Battelle Pacific Northwest Division, Richland, Washington 99352, USA.
Toxicological Sciences (Impact Factor: 4.48). 06/2005; 85(1):476-90. DOI: 10.1093/toxsci/kfi119
Source: PubMed

ABSTRACT An extensive database on the toxicity and modes of action of ethylene glycol (EG) has been developed over the past several decades. Although renal toxicity has long been recognized as a potential outcome, in recent years developmental toxicity, an effect observed only in rats and mice, has become the subject of extensive research and regulatory reviews to establish guidelines for human exposures. The developmental toxicity of EG has been attributed to the intermediate metabolite, glycolic acid (GA), which can become a major metabolite when EG is administered to rats and mice at high doses and dose rates. Therefore, a physiologically based pharmacokinetic (PBPK) model was developed to integrate the extensive mode of action and pharmacokinetic data on EG and GA for use in developmental risk assessments. The resulting PBPK model includes inhalation, oral, dermal, intravenous, and subcutaneous routes of administration. Metabolism of EG and GA were described in the liver with elimination via the kidneys. Metabolic rate constants and partition coefficients for EG and GA were estimated from in vitro studies. Other biochemical constants were optimized from appropriate in vivo pharmacokinetic studies. Several controlled rat and human metabolism studies were used to validate the resulting PBPK model. When internal dose surrogates were compared in rats and humans over a broad range of exposures, it was concluded that humans are unlikely to achieve blood levels of GA that have been associated with developmental toxicity in rats following occupational or environmental exposures.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The distributed cure rate, which is assumed to be a stochastic variable with a specific distribution, is introduced into the SIS (Susceptible-Infected-Susceptible) to study the spreading behavior taking place upon complex networks. Through large scale numerical simulations, we find that this kind of distributed cure rate can greatly speed up the disease spreading behavior and promote the epidemic outbreaks among the population. Current results are very important for us to understand the virus spreading behavior on large technological networks.
    Energy Procedia 01/2011; 5:1411-1415. DOI:10.1016/j.egypro.2011.03.244
  • Women s Studies International Forum 01/2001; 24(5):617–618. DOI:10.1016/S0277-5395(01)00200-X · 0.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A compilation of rat tissue-to-blood partition coefficient data obtained both in vitro and in vivo in thirteen different tissues for a total of 309 different drugs is presented. An evaluation of the relationship between several fundamental physicochemical molecular descriptors and these distribution parameters was made. In addition, the ability to predict the Human Volume of distribution by regression analysis and by a Physiologically-Based approach was also tested. Results have shown different trends between the drug classes and tissues, consistent with earlier described relationships between physicochemical properties and pharmacokinetic behaviour. It was also possible to conclude for the acceptable ability to predict the volume of distribution in Humans by both regression and mechanistic approaches, which suggests that this type of data represents a convenient tool to describe the drug distribution on a new drug development context. These observations and analyses, along with the large database of rat tissue distribution data, should enable future efforts aimed toward developing a full in silico quantitative structure-pharmacokinetic relationships and improving our understanding of the correlations between fundamental chemical characteristics and drug distribution.
    European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 08/2013; DOI:10.1016/j.ejps.2013.08.020 · 3.01 Impact Factor

Full-text (2 Sources)

Available from
May 23, 2014